Penn Medicine Abramson Cancer Center


 

ASH 2019 Update on Novel Therapies for Higher Risk MDS: IDH Inhibitors, Azacitidine Combinations (Ven+Aza & Magrolimab+Aza), Targeting TP53 Mutations

21 views
February 24, 2020
Comments 0
Login to view comments. Click here to Login